ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

By Alberico L. Catapano, Željko Reiner, G. D. Backer, I. Graham, Marja-Riitta Taskinen, O. Wiklund, S. Agewall, E. Alegrı́a, M. Chapman, P. Durrington and 9 more. European Heart Journal, 2011

1,417 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, methodology): “These risk categories are compatible with the joint European Atherosclerosis Society/ESC lipid guidelines.(70) The joint guidelines offer further advice on lipid intervention based on these risk”
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “As detailed in the recent ESC/EAS Guidelines [653], when overt CHD is present, there is clear evidence that statins should be administered to achieve low-density lipoprotein cholesterol levels <1.”
The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. (2015, background): “Regarding dyslipidaemias, the European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS) guidelines do not recommend measuring hsCRP as a secondary target of therapy for everybody; however, it may be useful in people close to the highrisk category to better stratify their total risk ”